Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
The Future of Machine Learning in Predicting the Treatment Responses...
share announcement

The Future of Machine Learning in Predicting the Treatment Responses of Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: 30 July 2024 | Viewed by 1057

Special Issue Editors

Prof. Dr. Alfredo Vellido

E-Mail Website
Guest Editor
IDEAI_UPC Research Center, Universitat Politècnica de Catalunya (UPC BarcelonaTech), 08034 Barcelona, Spain
Interests: machine learning; data science; artificial intelligence; cancer
Dr. Ana Candiota

E-Mail Website
Guest Editor
1. Centro de Investigación Biomédica en Red: Bioingeniería, Biomateriales y Nanomedicina, 08193 Cerdanyola del Vallès, Spain
2. Departament de Bioquímica i Biologia Molecular, Facultat de Biociències, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain
Interests: magnetic resonance spectroscopy; imaging biomarkers; preclinical tumour models; MR contrast agents; brain tumours; magnetic resonance imaging
Special Issues, Collections and Topics in MDPI journals
Dr. Margarida Julia-Sape

E-Mail Website
Guest Editor
Departament de Bioquímica i Biologia Molecular, Institut de Biotecnologia I de Biomedicina, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Valles, Spain
Interests: precision medicine; prospective evaluation; clinical trial; decision-support tool; added value; non-invasive biomarkers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

After decades of research, machine learning (ML), understood as a toolbox for data analysis in medical applications, is now widely recognized as useful but only scantly applied in real medical practice. Oncology is, arguably, one of the pioneering domains in medicine in the research and development of ML-based analytical strategies. This can be at least partially explained by the many successes achieved in the analysis of medical image. A cancer-related problem that still requires much research from this point of view is the prediction of treatment responses. This includes the investigation of responses to new and experimental drugs and often involves pre-clinical studies.

This Special Issue welcomes innovative research on the use of artificial intelligence (AI) in general and ML in particular (including deep learning) for the analysis of any type of data related to the general problem of the prediction of treatment responses in cancers. This would include studies in, amongst others, clinical and pre-clinical settings and pharmacology. Contributions on personalized medicine, explainable AI, multi-modal data analysis, or data visualization, applied to or involving treatment response measures such as progression-free survival, amongst other topics, are welcome.

Prof. Dr. Alfredo Vellido
Dr. Ana Candiota
Dr. Margarida Julia-Sape
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer treatment response
  • medical decision support systems
  • cancer outcome prediction
  • personalized medicine
  • pre-clinical models
  • artificial intelligence
  • machine learning
  • deep learning
  • progression-free survival
  • disease-free survival
  • event-free survival
  • overall survival
  • adverse event
  • quality of life
  • surrogate endpoint

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

25 pages, 4536 KiB  
Article
Comparing Performances of Predictive Models of Toxicity after Radiotherapy for Breast Cancer Using Different Machine Learning Approaches
by Maria Giulia Ubeira-Gabellini, Martina Mori, Gabriele Palazzo, Alessandro Cicchetti, Paola Mangili, Maddalena Pavarini, Tiziana Rancati, Andrei Fodor, Antonella del Vecchio, Nadia Gisella Di Muzio and Claudio Fiorino
Cancers 2024, 16(5), 934; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers16050934 - 25 Feb 2024
Viewed by 780
Abstract
Purpose. Different ML models were compared to predict toxicity in RT on a large cohort (n = 1314). Methods. The endpoint was RTOG G2/G3 acute toxicity, resulting in 204/1314 patients with the event. The dataset, including 25 clinical, anatomical, and dosimetric features, was [...] Read more.
Purpose. Different ML models were compared to predict toxicity in RT on a large cohort (n = 1314). Methods. The endpoint was RTOG G2/G3 acute toxicity, resulting in 204/1314 patients with the event. The dataset, including 25 clinical, anatomical, and dosimetric features, was split into 984 for training and 330 for internal tests. The dataset was standardized; features with a high p-value at univariate LR and with Spearman ρ>0.8 were excluded; synthesized data of the minority were generated to compensate for class imbalance. Twelve ML methods were considered. Model optimization and sequential backward selection were run to choose the best models with a parsimonious feature number. Finally, feature importance was derived for every model. Results. The model’s performance was compared on a training–test dataset over different metrics: the best performance model was LightGBM. Logistic regression with three variables (LR3) selected via bootstrapping showed performances similar to the best-performing models. The AUC of test data is slightly above 0.65 for the best models (highest value: 0.662 with LightGBM). Conclusions. No model performed the best for all metrics: more complex ML models had better performances; however, models with just three features showed performances comparable to the best models using many (n = 13–19) features. Full article
(This article belongs to the Special Issue The Future of Machine Learning in Predicting the Treatment Responses of Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop